Background: Integrating molecularly targeted agents with cytotoxic drugs used in curative treatment of pediatric cancers is complex. An evaluation was undertaken with the ERBB3/Her3-specific antibody patritumab (P) either alone or with the ERBB1/epidermal growth factor receptor inhibitor erlotinib (E) in combination with standard cytotoxic agents, cisplatin, vincristine, and cyclophosphamide, in pediatric sarcoma xenograft models that express receptors and ligands targeted by these agents.
is expressed in rhabdomyosarcoma, particularly the alveolar subtype, and has been proposed as a therapeutic target 9 as RNAi-mediated knockdown of ERBB3 in RD embryonal rhabdomyosarcoma cells suppresses proliferation. However, as noted by Gilbertson, 8 overexpression of a drug target does not necessarily predict for therapeutic efficacy. For example, Norberg et al. 9 proposed overexpression of the EphA2 receptor as a possible target in sarcoma. To validate EphA2 as a target, these authors cited the activity of dasatinib (which has inhibitory activity against EphA2) in osteosarcoma xenografts.
Yet the tumor inhibitory activity was marginal in these models. 10 In adult cancers, therapeutic efficacy of targeted drugs such as lapatinib or trastuzumab occurs when the target gene is amplified (as in ERBB2/Her2 amplified breast cancer 11 ), and where there exists an activating mutation (imatinib in treatment of chronic myelogenous leukemia 12 ). In pediatric cancers, certain mutations in ALK in neuroblastoma 13 and activation of ALK through t(2;5)(p23;q35) chromosomal translocation, amplification, or mutation 14 confer sensitivity to crizotinib.
Although ERBB3 does not signal directly, 15, 16 it heterodimerizes with and allosterically activates ERBB1 and ERBB2. Expression of ERBB3 has a negative prognostic impact on survival of patients with breast or lung carcinoma. 17 Thus, ERBB3 has become a focus for targeted therapy. 18 Additionally, anti-ERBB3 therapy was also been reported to sensitize erlotinib refractory nonsmall cell lung cancer. 19 Further, the expression level of the ERBB3 ligand, heregulin (HRG), appears to be a biomarker for response to therapy with patritumab, an anti-ERBB3 monoclonal antibody, in nonsmall cell lung cancer (NSCLC) patients. 20 However, these results were based upon a small subgroup analysis and were not confirmed in the HER3-Lung study. 21 In previous studies using antibodies directed against the type I insulin-like growth factor receptor (IGF1R), we showed several sarcoma xenografts regressed following treatment; however, the majority of sarcoma (and other tumor types) were intrinsically resistant to IGF1R-targeted therapy. 22, 23 While resistance to IGF1R-targeted antibodies was associated with expression of the insulin receptor, 24 this did not explain the intrinsic resistance present in many tumor models. In vitro, intrinsic resistance, and acquired resistance to IGF-1R-targeted antibodies was associated with constitutive expression of ERBB-family receptors, or rapid induction of alternative growth factor receptors including ERBB1, ERBB2, and ERBB3. 25 Using the Pediatric Preclinical Testing Program (PPTP) cell line and xenograft gene expression database, we probed expression of ERBB family members and observed high-level expression of ERBB3 predominantly in alveolar rhabdomyosarcoma models and ERBB1 in embryonal rhabdomyosarcoma. Using phosphotyrosine arrays, we observed expression of activated ERBB1 and ERBB3 in many Ewing sarcoma cell lines. 25 Thus, it was of interest to evaluate the ERBB3-targeted antibody patritumab alone or combined with erlotinib, a small molecule inhibitor of ERBB1/2, 26 and to evaluate if either drug or these drugs in combination had significant antitumor activity. As development of such targeted therapeutics will involve integration with cytotoxic agents, we asked whether these agents could enhance the activity of standard of care cytotoxic therapy used in the treatment of childhood sarcomas.
MATERIALS AND METHODS

Gene expression profiling
Relative expression of ERBB3/Her3, ERBB1 (EGFR), and HRG mRNA was determined on PPTP tumors and cell lines using data derived from Agilent Sureprint 3 arrays. Data were processed by selecting the median for each foreground signal. The differences caused by batch effects were addressed by quantile normalization across all arrays. For each tumor line, the average of all replicates was calculated as a gene expression measure.
Pharmacodynamics studies
In vitro, cell lines were screened for expression of phosphorylated-ERBB3, ERBB3, and HRG. For ES-4 cells, that showed the highest levels of phospho-ERBB3, the effect of patritumab was studied after 24-hr exposure to 5-20 g/ml antibody. The effect of patritumab, erlotinib, or the combination was studied in vivo using ES-4 xenografts. Mice bearing ES-4 xenografts were untreated or treated with patritumab (60 mg/kg day 0, and day 3), erlotinib (100 mg/kg days 1-3), or the combination. Tumors were harvested 24 hr after the last drug administration (i.e., 96 hr after starting therapy).
Western blotting
Tumor tissues and cell lines were snap frozen and immunoblotting was performed as previously described. 27 Antibodies used were against ERBB3 (D22C5 Rabbit mAb), phospho-ERBB3 (Y1289; D1B5 Rabbit mAb), HRG (#2573 Rabbit Ab), and GAPDH (D16H11 rabbit Mab; loading control), which were purchased from Cell Signaling Tecnology (Danvers, MA). Antibodies were used at 1:1,000 dilutions except for GAPDH (1:5,000). The protein bands were quantified using Image Studio software for western analysis. The signal was determined for each band, and GAPDH was used to normalize (band signal/GAPDH signal).
Toxicity testing
The maximum tolerated dose (MTD) for vincristine and cyclophosphamide administered weekly for four consecutive weeks was 1 mg/kg and 150 mg/kg, respectively. The MTD for cisplatin was 4 mg/kg administered one time. Cohorts of nontumor bearing mice (n = 5) were dosed with single agents or combinations of patritumab plus cytotoxic agent or patritumab combined with erlotinib plus the individual cytotoxic agent. Mice were weighed daily. The dose resulting in no deaths and a maximum of 10% body weight loss was selected for further testing.
In Vivo evaluation
Single agents and combinations were evaluated in three sarcoma models, ES-2 and ES-4 Ewing sarcomas and Rh18 embryonal rhabdomyosarcoma. Tumors were propagated as subcutaneous xenografts in female CB17 scid mice as described previously. 28 All procedures and data analysis were as described in Ref. 28 . Ten mice per treatment group were used. All experiments were conducted under protocols approved by the IACUC at UTHSCSA.
Statistical methods
Treatment groups were compared with regard to time to event with log rank tests. Treatment groups were compared with regard to T/C assessment day with Wilcoxon tests. All statistical testing was two sided and corrected for multiple comparisons with the Bonferroni method and an experimentwise significance level of 5%. SAS Version 9.4 for Windows (SAS Institute, Cary, NC) was used throughout. For all experiments, tumor volume at start of treatment was similar for all treatment and control groups (mean ± SE = 0.264 ± 0.00644 cm 3 ; n = 536).
Drug formulation and administration
Lyophilized patritumab was formulated in phosphate buffered saline and administered intravenously at 25 mg/kg twice weekly for four con- 
RESULTS
Selection of tumor models
mRNA expression of ERBB3, ERBB1, and HRG (the ligand for ERBB3) were determined across the PPTP panels of cell lines and xenografts including solid tumors, brain tumors, and acute lymphoblastic leukemias (the highest expression in 19 lines of 96 is shown) (Fig. 1A) . Of note, of the 10 highest lines expressing ERBB3, six are derived from alveolar RMS xenografts. ERBB3 protein was relatively abundant in alveolar RMS lines (Rh5, Rh10, Rh41) and was detected at lower levels in other alveolar and embryonal RMS cell lines (Fig. 1B) .
While ERBB3 was expressed at the mRNA level in several Ewing sarcoma models, ERBB3 protein was detected only in ES-4, Ewing sarcoma cells, and this line also expressed the highest level of phospho-ERBB3 (Y1289). Phospho-ERBB3 (Y1289) was detected at low levels in ES-2 and also in Rh18, although the level of ERBB3 was lower than in other rhabdomyosarcoma models. HRG was detected in all of the sarcoma lines examined. ERBB3 protein was barely detected in Ewing sarcoma lines other than ES-4. In contrast, RMS models Rh5, Rh10, and Rh41 expressed ERBB3 at high levels, but there was no detectable phospho-ERBB3 despite detectable levels of HRG. ERBB1 protein was detected in five of eight Ewing sarcoma cell lines, with highest expression in ES-4, and was detected in all of the RMS lines except Rh5 (Fig. 1C ). Rh18 embryonal RMS had the highest expression of ERBB1 of all models. The effect of increasing concentrations (5-20 g/ml) of patritumab was examined in ES-4 cells. Cells were exposed to patritumab for 24 hr, and levels of pERBB3, pAKT, pERK1/2, and total proteins determined. As shown in Figure 1D (and quantified in Fig. 1E ), increasing concentrations of patritumab resulted in decreased pERBB3 (∼46% decrease), pERK1 (∼57%), and an increase in pAKT at the 20 g/ml patritumab concentration (∼45%).
Toxicity of combinations
Patritumab was tolerated at 25 mg/kg twice weekly for four consecutive weeks with minimal weight loss (maximum ∼2%), whereas patritumab combined with erlotinib (75 mg/kg/day) resulted in a maximum of 6% weight loss. The MTD for vincristine and cyclophosphamide administered weekly for four consecutive weeks was 1 mg/kg and 150 mg/kg, respectively. The MTD for cisplatin was 4 mg/kg administered one time. The addition of patritumab did not necessitate dose reduction for any cytotoxic agent. In contrast, when patritumab was combined with erlotinib, the doses of vincristine and cisplatin had to be reduced to 75% of the MTD, and the dose of cyclophosphamide had to be reduced to 75 mg/kg/week (50% of the MTD) ( Supplementary   Fig. S1 ).
Evaluation of patritumab, erlotinib, or both agents combined
Based on the potential "activation" of ERBB3, determined by phospho-ERBB3(Y1289), and levels of ERBB1 expression, we selected ES-4, ES-2, and Rh18 xenografts against which to evaluate patritumab and erlotinib. Statistical analysis for all studies is presented in Table 1 .
Additional details of testing are provided including total numbers of mice, number of mice that died (or were otherwise excluded), numbers of mice with events and average times to event, tumor growth delay, as well as numbers of responses and T/C values (Supplementary Table S1 ). Patritumab did not induce statistically significant growth delay in any tumor model, whereas erlotinib had slight activity reaching significance only against Rh18 embryonal rhabdomyosarcoma (P = 0.016). Patritumab combined with erlotinib had very modest activity and did not delay tumor progression significantly in any model (Table 1) . Statistical comparisons between patritumab and erlotinib as single agents compared to their activity in combination are also shown in Supplementary Table S2.
Evaluation of patritumab with cytotoxic agents
As a second phase for testing, we combined patritumab with vincristine, cisplatin, or cyclophosphamide. Full doses of each cytotoxic agent were tolerated in combination with patritumab. For ES-2 xenografts, only cyclophosphamide or cyclophosphamide + P significantly inhibited tumor growth (P < 0.001). Tumor control for patritumab combined with vincristine was not significantly different Table S2 ). ES-4 xenografts were more sensitive to cytotoxic agents, particularly cyclophosphamide and vincristine (Table 1) . Patritumab significantly potentiated the antitumor activity of vincristine (P = 0.037) and cisplatin (P = 0.008) over these agents administered at their respective Table S2 ). Patritumab also potentiated the activity for cyclophosphamide; however, this did not meet significance (P = 0.154). However, the effect of patritumab potentiating the activity of these cytotoxic agents was observed only in ES-4 xenografts (Fig. 2) .
MTDs (Supplementary
Evaluation of patritumab combined with erlotinib and cytotoxic agents
The third phase of testing combined patritumab with erlotinib (P + E) with each of the three cytotoxic agents. It required dose reduction of vincristine from 1 to 0.75 mg/kg/dose, cisplatin from 4 to 3 mg/kg, and cyclophosphamide from 150 to 75 mg/kg/dose. In ES-4 xenografts, there was no significant difference between vincristine or cisplatin combined with P + E compared to the MTD for each cytotoxic agent alone (Supplementary Table S2) . Similar results were TA B L E 1 Summary of in vivo activity of patritumab, erlotinib alone, or in combination with cytotoxic agents Table S1 ).
Tumor line Treatment group Median time to event P-value EFS T/C Tumor volume T/C EFS activity Response
Pharmacodymanic studies
To determine whether patritumab and erlotinib, at the doses and schedules used, inhibited their molecular targets, we chose to study their effects on ES-4 xenografts as this line in vitro had the most robust phosphorylation of ERBB3. Tumor-bearing mice received patritumab (60 mg/kg) on day 0 and day 3, whereas erlotinib (75 mg/kg) was administered daily for 3 days as single agents, or the same doses and schedules for combined treatment. Tumors were excised 24 hr after the last drug dose. As shown in Figure 4 , phospho-ERBB3 (Tyr1289) was detected in control tumors (n = 3), with some variability, but xenograft models tested at dose levels of drug giving clinically relevant exposures. 37 The results of our current study further emphasize that high-level expression or activation of a signaling pathway does not necessarily constitute a valid target for therapy in the absence of a known activating mutation or translocation.
ERBB3 is unique to the ERB family of receptors in that evolutionary divergence within the kinase domain has led to the protein being in a constitutively inactive conformation. [38] [39] [40] Recent evidence has shown that the ERBB3 kinase domain is a highly specialized allosteric activator of its ERBB partners. 16 The rationale for combining an ERBB3
inhibitor with an ERBB1/2 inhibitor (erlotinib) is that this may inhibit dimerization and signaling through hybrid receptors and may prevent resistance to ERBB1/2 directed therapy. 16 Our studies showed that relative to other pediatric xenografts and cell lines developed in the PPTP, ERBB1 mRNA was high in embryonal rhabdomyosarcoma lines (Rh18 and RD), whereas ERBB3 mRNA was highly expressed Patritumab has been shown to inhibit ERBB3 at doses similar or lower than used in this study. 41 We selected ES-4 xenografts, as this cell line showed the highest phosphorylation of ERBB3. In ES-4 xenografts, patritumab completely suppressed ERBB3 phosphorylation, confirming that at the dose and schedule used this antibody effectively inhibited its target. Erlotinib, a small molecule inhibitor of ERBB1/2, had no effect on phospho-ERBB3, as anticipated. However, evidence of target inhibition was shown by suppression of ERK1/2 downstream of the receptors targeted by this agent. Of note, erlotinib induced an increase in phospho-Akt, suggesting compensation for ERBB1/2 inhibition. Importantly, the combination of patritumab with erlotinib completely suppressed phospho-ERBB3 and ∼90% decrease in phospho-ERK1/2 and prevented erlotinib-induced phosphorylation of Akt. However, as discussed below, the combination had very modest effect on growth of ES-4 xenografts.
Patritumab combined with erlotinib showed promising efficacy in early phase clinical trials for treatment of NSCLC, 42 and when combined with trastuzumab and paclitaxel in ERBB2 overexpressing metastatic breast cancer. 17 When tested against our pediatric sarcoma xenografts, patritumab, as a single agent, was devoid of significant antitumor activity, whereas erlotinib induced marginal, although statistically significant, inhibition of Rh18 tumor growth. Erlotinib treatment induced statistically significant growth delay in only one of three models. However, the magnitude of these effects was quite marginal, and the combination of patritumab with erlotinib did not significantly retard tumor growth. Development of this combination in NSCLC as the first part of the phase 3 study did not meet predefined efficacy criteria, hence further development was terminated. 21 Because of the potential for erlotinib to alter the clearance of drugs such as vincristine, we chose to evaluate patritumab with cytotoxic agents before combining this agent with erlotinib and cyto- hence likely decreasing clearance of vincristine. 44, 45 The cause of the interaction between patritumab-erlotinib and cisplatin or cyclophosphamide is less clear, but may be related to the ERB pathway regulating DNA damage repair. 46, 47 Of note, the addition of erlotinib to patritumab resulted in less antitumor activity than observed when these cytotoxic agents were combined with patritumab alone. This was particularly apparent for cyclophosphamide, probably as a consequence of the reduced cyclophosphamide dose tolerated, where the combination with patritumab and erlotinib was significantly less active than cyclophosphamide administered at the MTD.
Our study demonstrates the potential, but also the challenges of integrating targeted therapeutics with conventional cytotoxic therapy.
While patritumab modestly potentiated the activity of each cytotoxic agent in one of three xenograft models, the addition of erlotinib neces- was detected. In our preclinical study, levels of HRG were similar in each tumor model, and did not associate with better response to patritumab alone or in combination with erlotinib; hence, these preclinical results are consistent with the NSCLC clinical trials. 21 In our study, including erlotinib with patritumab led to a decrease in the therapeutic activity of cyclophosphamide when compared to single-agent activity when administered at full dose levels (i.e., MTD). These data emphasize the need for a clear understanding the interaction of chemotherapy and targeted therapy combinations prior to clinical evaluation in pediatric cancer patients.
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